The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo ...

Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...

The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the ...

It covers all indications on the current Opdivo label for adults with solid tumours, including as monotherapy, for maintenance following completion of the checkpoint inhibitor plus Yervoy ...

European Commission approves Bristol Myers Squibb’s Opdivo plus Yervoy for first-line treatment of adult patients with unresectable or advanced HCC: Princeton, New Jersey Monday ...

benefit when Opdivo (nivolumab) is used with platinum-doublet chemotherapy as a neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC) patients. The open-label, randomised ...

BMY is banking on new drugs to offset generic competition for older drugs. However, this might not be enough as the outlook ...

Bristol Myers Squibb has bolstered its case for Opdivo to be used as a preoperative treatment for non-small cell lung cancer (NSCLC) as it has delivered an overall survival (OS) edge when added to ...

Opdivo plus Yervoy showed a median overall survival of 23.7 months vs. 20.6 months with lenvatinib or sorafenib in the CheckMate -9DW trial. The overall response rate for Opdivo plus Yervoy was 36 ...

CheckMate-816 is a randomized, open-label, multi-center trial which is evaluating the efficacy of Opdivo in combination with chemotherapy versus chemotherapy alone as a neoadjuvant treatment for ...